BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31589081)

  • 1. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.
    Ke X; Eisenberg Lawrence DF; Oglesby A; Patel J; Kan H; Boggs R
    Clin Ther; 2015 Dec; 37(12):2852-63. PubMed ID: 26547483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
    Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
    Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study.
    Joo YB; Sung YK; Shim JS; Kim JH; Lee EK; Lee HS; Bae SC
    Rheumatol Int; 2015 May; 35(5):879-86. PubMed ID: 25300729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States.
    Narayanan S; Wilson K; Ogelsby A; Juneau P; Durden E
    J Occup Environ Med; 2013 Nov; 55(11):1262-70. PubMed ID: 24202242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.
    Kabadi S; Yeaw J; Bacani AK; Tafesse E; Bos K; Karkare S; DeKoven M; Vina ER
    Lupus; 2018 Oct; 27(11):1799-1809. PubMed ID: 30068254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    J Med Econ; 2020 Jul; 23(7):786-799. PubMed ID: 32149541
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic burden of sarcoidosis in a commercially-insured population in the United States.
    Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
    J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US.
    Slawsky KA; Fernandes AW; Fusfeld L; Manzi S; Goss TF
    Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1224-32. PubMed ID: 21584945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
    Jiang M; Near AM; Desta B; Wang X; Hammond ER
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study.
    McCormick N; Marra CA; Sadatsafavi M; Aviña-Zubieta JA
    Lupus; 2018 Jul; 27(8):1247-1258. PubMed ID: 29665755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
    Wu SS; Perry A; Tkacz J; Bryant G
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
    [No Abstract]   [Full Text] [Related]  

  • 17. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease.
    Karve S; Candrilli S; Kappelman MD; Tolleson-Rinehart S; Tennis P; Andrews E
    J Pediatr; 2012 Oct; 161(4):662-670.e2. PubMed ID: 22578787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.
    Jönsen A; Hjalte F; Willim M; Carlsson KS; Sjöwall C; Svenungsson E; Leonard D; Bengtsson C; Rantapää-Dahlqvist S; Pettersson S; Gunnarsson I; Zickert A; Gustafsson JT; Rönnblom L; Petersson IF; Bengtsson AA; Nived O
    Semin Arthritis Rheum; 2016 Jun; 45(6):684-90. PubMed ID: 26743074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
    Bell CF; Ajmera MR; Meyers J
    Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.